DNA Medicine Institute Awarded NIH Grant for Emergency Point-of-Care Blood Sensor

– Grant accelerates development of a palm-sized device that replicates full hospital blood testing –
Cambridge, MA — March 9 /PRNewswire/ — The DNA Medicine Institute, a leader in breakthrough medical diagnostics, announced today it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The funding supports the development of a next-generation emergency blood sensor, engineered to compress the capabilities of a full-scale hospital hematology analyzer — currently the size of a small refrigerator — into a compact, handheld device.

This innovation is designed to bring critical blood analysis directly to the point of care, allowing rapid assessment of life-threatening conditions by minimally trained personnel in virtually any environment. Intended use cases span hospitals, emergency rooms, ambulances, physician offices, battlefield or disaster zones, global health clinics, and other remote deployments.

The technology is expected to integrate into the Institute’s broader Universal Blood Sensor platform, which aims to bring comprehensive hospital-grade testing to a portable device that can be used anytime, anywhere, without reliance on centralized labs.

“We are proud to have the support of the NIH in advancing a diagnostics platform with the power to significantly reshape emergency medicine,” said Eugene Y. Chan, M.D., President and Chief Scientific Officer of the DNA Medicine Institute. “The NHLBI recognizes the profound impact of an accessible, real-time blood sensor capable of rapidly diagnosing acute blood loss, sepsis, and other critical conditions. This award accelerates our mission to bring transformative testing capabilities directly to the hands of those who need it most.”